CIGNA Corporate Services Reports $50,000 in Lobbying Efforts
In a recent Lobbying Disclosure Act filing, CIGNA CORPORATE SERVICES LLC AND ITS AFFILIATES disclosed $50,000 in lobbying expenditures for the first quarter of 2025. The lobbying efforts focused on various health care policy issues, particularly those related to coverage and the cost of care.
CI Congressional Stock Trading Insights
In the past six months, members of Congress have engaged in trades involving $CI stock seven times. Among these trades, there were three purchases and four sales.
Below is a summary of recent congressional stock trading activity for $CI during the last six months:
To stay updated on congressional stock trades, visit Quiver Quantitative’s congressional trading dashboard.
CI Insider Trading Activities
Insiders at CIGNA have conducted four open market trades of $CI stock over the last six months, with no purchases and four sales recorded.
Here is a detailed list of the recent trades by insiders:
- DAVID CORDANI (Chairman & CEO) sold 26,527 shares for an estimated $8,173,499
- NOELLE K EDER sold 9,944 shares for an estimated $3,182,080
- NICOLE S JONES sold 4,904 shares for an estimated $1,511,020
- ELDER GRANGER sold 2,376 shares for an estimated $737,391
To monitor insider transactions, access Quiver Quantitative’s insider trading dashboard.
CI Hedge Fund Activity Overview
During the most recent quarter, 636 institutional investors increased their holdings in $CI stock, while 834 reduced their positions. This reflects a dynamic shift in investment strategies.
Here are some significant recent investment moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 2,623,729 shares (+inf%) in Q4 2024, totaling an estimated $724,516,526
- FMR LLC decreased holdings by 1,764,916 shares (-12.4%) in Q4 2024, valued at approximately $487,363,904
- JPMORGAN CHASE & CO added 1,317,489 shares (+35.0%) in Q4 2024, worth about $363,811,412
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,117,751 shares (-9.3%) in Q4 2024, equating to around $308,655,761
- BOSTON PARTNERS decreased positions by 1,080,728 shares (-62.7%) in Q4 2024, valued at an estimated $298,432,229
- BLACKROCK, INC. reduced holdings by 751,711 shares (-3.1%) in Q4 2024, amounting to about $207,577,475
- GQG PARTNERS LLC added 737,099 shares (+22.4%) in Q4 2024, totaling an estimated $203,542,517
To explore hedge funds’ stock portfolios, check Quiver Quantitative’s institutional holdings dashboard.
CI Analyst Ratings and Price Targets
In recent months, Wall Street analysts have weighed in on $CI, with five firms issuing buy ratings and none issuing sell ratings.
Below are recent analyst assessments:
- Cowen & Co. issued a “Buy” rating on 02/03/2025
- Piper Sandler issued an “Overweight” rating on 02/03/2025
- Raymond James provided a “Strong Buy” rating on 01/31/2025
- Morgan Stanley characterized the stock as “Overweight” on 01/31/2025
- Stephens rated it as a “Buy” on 10/23/2024
To review analyst ratings and price targets for CI, visit Quiver Quantitative’s $CI forecast page.
Recent Price Target Updates
In the last six months, multiple analysts have provided price targets for $CI, suggesting a median target of $355.0.
Below are the latest targets:
- Stephen Baxter from Wells Fargo set a target price of $341.0 on 02/04/2025
- Jessica Tassan from Piper Sandler set a target price of $348.0 on 02/03/2025
- John Ransom from Raymond James set a target price of $360.0 on 01/31/2025
- Erin Wright from Morgan Stanley set a target price of $379.0 on 01/31/2025
- Ben Hendrix from RBC Capital set a target price of $355.0 on 01/31/2025
This article is not financial advice. For more information, see Quiver Quantitative’s disclaimers.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
